Genomics of lung cancer

Published on January 31, 2016   39 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Cancer Genetics

Hello, I am Ramaswamy Govindan, medical oncologist at the Washington University School of Medicine in St. Louis. I'm an expert in lung cancer and cancer genomics. Today, we're going to talk about the genomics of lung cancer.
I have no conflicts relevant to this presentation. I'm a consultant for BMS, BI, Pfizer, Mallinckrodt Medical, Genentech, Novartis, and GlaxoSmithKline.
I want to acknowledge the investigators from the Cancer Genome Atlas Project. I specifically want to thank Dr. Matthew Meyerson and Steve Baylin, my two co-chairs for their support. I also want to thank my colleagues at the Washington University School of Medicine, specifically those at the Genome Institute, Dr. Richard Wilson, Dr. Elaine Mardis, and Dr. Li Ding for their collaboration.
I want to begin with a story. This is actually a patient of mine with advanced non-small cell lung cancer who came to see me after receiving multiple lines of chemotherapy. When we saw her, she had advanced disease, and she had a lot of symptoms related to her cancer. She was unable to work full-time. We biopsied her tumor. As you can see here, she has a fairly large and impressive tumor on the right side. The biopsy showed a 12 base pair insertion exon 20 of the ERBB2 gene. This is a known oncogenic alteration seen in a small number of patients with non-small cell lung cancer. When we treated her as a part of the phase 1 study with neratinib and temsirolimus, she had an impressive response as you can see here from before treatment and after treatment, and she had a very nice decrease in the tumor size and had significant benefit clinically as well as radiographically. She in fact went back to work full-time and worked for nearly a year before the cancer progressed and she is now currently on salvage chemotherapy. But she had a very good one year, the combination of neratinib and temsirolimus because of the recognition that her tumor had this activating mutation in the ERBB2 gene.